Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predictive and prognostic impact of tumour-infiltrating lymphocytes in triple-negative breast cancer treated with neoadjuvant chemotherapy.
Herrero-Vicent C, Guerrero A, Gavilá J, Gozalbo F, Hernández A, Sandiego S, Algarra MA, Calatrava A, Guillem-Porta V, Ruiz-Simón A. Herrero-Vicent C, et al. Among authors: guillem porta v. Ecancermedicalscience. 2017 Aug 15;11:759. doi: 10.3332/ecancer.2017.759. eCollection 2017. Ecancermedicalscience. 2017. PMID: 28900472 Free PMC article.
Phase II trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with ER/PgR[+] operable breast cancer.
Llombart-Cussac A, Guerrero Á, Galán A, Carañana V, Buch E, Rodríguez-Lescure Á, Ruiz A, Fuster Diana C, Guillem Porta V. Llombart-Cussac A, et al. Among authors: guillem porta v. Clin Transl Oncol. 2012 Feb;14(2):125-31. doi: 10.1007/s12094-012-0771-9. Clin Transl Oncol. 2012. PMID: 22301401 Clinical Trial.
A prognostic index for locoregional recurrence after neoadjuvant chemotherapy.
Herrero-Vicent C, Guerrero-Zotano A, Gavilá-Gregori J, Hernández-Blanquisett A, Sandiego-Contreras S, Samper-Hiraldo JM, Guillem-Porta V, Ruiz-Simón A. Herrero-Vicent C, et al. Among authors: guillem porta v. Ecancermedicalscience. 2016 Jun 16;10:647. doi: 10.3332/ecancer.2016.647. eCollection 2016. Ecancermedicalscience. 2016. PMID: 27433280 Free PMC article.
Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy.
Gianni L, Baselga J, Eiermann W, Guillem Porta V, Semiglazov V, Lluch A, Zambetti M, Sabadell D, Raab G, Llombart Cussac A, Bozhok A, Martinez-Agulló A, Greco M, Byakhov M, Lopez Lopez JJ, Mansutti M, Valagussa P, Bonadonna G; European Cooperative Trial in Operable Breast Cancer Study Group. Gianni L, et al. Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8715-21. doi: 10.1158/1078-0432.CCR-05-0539. Clin Cancer Res. 2005. PMID: 16361558 Clinical Trial.
Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients.
Baselga J, Llombart-Cussac A, Bellet M, Guillem-Porta V, Enas N, Krejcy K, Carrasco E, Kayitalire L, Kuta M, Lluch A, Vodvarka P, Kerbrat P, Namer M, Petruzelka L. Baselga J, et al. Ann Oncol. 2003 Sep;14(9):1383-90. doi: 10.1093/annonc/mdg368. Ann Oncol. 2003. PMID: 12954577 Free article. Clinical Trial.
Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial.
Chan A, Martin M, Untch M, Gil MG, Guillem-Porta V, Wojtukiewicz M, Kellokumpu-Lehtinen P, Sommer HL, Georgoulias V, Battelli N, Pawlicki M, Aubert D, Bourlard T, Gasmi J, Villanova G, Petruzelka L; Navelbine Herceptin Project. Chan A, et al. Br J Cancer. 2006 Oct 9;95(7):788-93. doi: 10.1038/sj.bjc.6603351. Epub 2006 Sep 12. Br J Cancer. 2006. PMID: 16969343 Free PMC article. Clinical Trial.
Social value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologists.
Camps-Herrero C, Paz-Ares L, Codes M, López-López R, Antón-Torres A, Gascón-Vilaplana P, Guillem-Porta V, Carrato A, Cruz-Hernández JJ, Caballero-Díaz C, Blasco-Cordellat A, Moreno-Nogueira JA, Díaz-Rubio E. Camps-Herrero C, et al. Among authors: guillem porta v. Clin Transl Oncol. 2014 Oct;16(10):914-20. doi: 10.1007/s12094-014-1170-1. Epub 2014 Jun 13. Clin Transl Oncol. 2014. PMID: 24924625
Oncologist's knowledge and implementation of guidelines for breakthrough cancer pain in Spain: CONOCE study.
López López R, Camps Herrero C, Khosravi-Shahi P, Guillem Porta V, Carrato Mena A, Garcia-Foncillas J, Cruz Hernández JJ, Gascón Vilaplana P, Antón Torres A, Diaz-Rubio E, Feyjoo Saus M, Aranda Aguilar E. López López R, et al. Among authors: guillem porta v. Clin Transl Oncol. 2018 May;20(5):613-618. doi: 10.1007/s12094-017-1756-5. Epub 2017 Oct 3. Clin Transl Oncol. 2018. PMID: 28975575
Breakthrough cancer pain: review and calls to action to improve its management.
Camps Herrero C, Batista N, Díaz Fernández N, Escobar Álvarez Y, Gonzalo Gómez A, Isla Casado D, Salud A, Terrasa Pons J, Guillem Porta V. Camps Herrero C, et al. Among authors: guillem porta v. Clin Transl Oncol. 2020 Aug;22(8):1216-1226. doi: 10.1007/s12094-019-02268-8. Epub 2020 Jan 30. Clin Transl Oncol. 2020. PMID: 32002739 Review.
Measures to evaluate quality of care in renal cancer: results of a Delphi study in Spain.
Guillem Porta V, Camps C, Climent Durán MÁ, Gallardo E, González Del Alba A, Lázaro-Quintela M, Méndez Vidal MJ, Pinto Marín Á, Puente J, Antón-Rodríguez C, Caballero-Martínez F, Campos-Lucas FJ, Lugo I, Rogado Á, Durán I. Guillem Porta V, et al. Clin Transl Oncol. 2022 Mar;24(3):495-502. doi: 10.1007/s12094-021-02703-9. Epub 2021 Sep 5. Clin Transl Oncol. 2022. PMID: 34482526
15 results